Prolonged survival with systemic chemotherapy in an advanced malignant mesothelioma: A case report.
Peritoneal mesothelioma
chemotherapy
surgery
survival
Journal
Rare tumors
ISSN: 2036-3605
Titre abrégé: Rare Tumors
Pays: England
ID NLM: 101526926
Informations de publication
Date de publication:
2021
2021
Historique:
received:
02
05
2019
accepted:
07
12
2020
entrez:
22
2
2021
pubmed:
23
2
2021
medline:
23
2
2021
Statut:
epublish
Résumé
Peritoneal mesotheliomas are very rare tumors. Their prognosis is poor, average survival does not exceed 1 year after peritoneal cytoreduction. Systemic chemotherapy is considered to have no proven value in the management of peritoneal mesotheliomas. Objective responses with systemic chemotherapy are very rare. We report here a case of an advanced peritoneal mesothelioma which achieved an unexpected partial response with chemotherapy, allowing the patient to have a right colectomy. The patient was referred to a specialized center on HIPEC, but taking in account the long awaiting interval, the HIPEC was judged to be inefficient and then the poursuit of 6 cycles of systemic chemotherapy was decided. The patient is still alive without any symptom and with a good performance status at 59 months after diagnosis. Throughout our case, we provide an encouraging evidence of the role of initial systemic chemotherapy in the downstaging of initially unresectable primary malignant mesothelioma and in the improvement of overall survival.
Identifiants
pubmed: 33613924
doi: 10.1177/2036361320984527
pii: 10.1177_2036361320984527
pmc: PMC7874336
doi:
Types de publication
Case Reports
Langues
eng
Pagination
2036361320984527Informations de copyright
© The Author(s) 2021.
Déclaration de conflit d'intérêts
Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
J Clin Oncol. 2008 Jul 20;26(21):3567-72
pubmed: 18640937
J Surg Oncol. 2011 Jun;103(8):822-31
pubmed: 21283990
Expert Rev Anticancer Ther. 2017 Sep;17(9):865-872
pubmed: 28594258
Eur J Cancer. 2013 Oct;49(15):3140-8
pubmed: 23831335
Cancer. 2011 May 1;117(9):1855-63
pubmed: 21509762
Ann Surg Oncol. 2013 Apr;20(4):1093-100
pubmed: 23456386
Surg Oncol. 2015 Mar;24(1):41-6
pubmed: 25680983
World J Gastroenterol. 2014 Sep 7;20(33):11700-12
pubmed: 25206274
Acta Chir Belg. 2004 Feb;104(1):114-7
pubmed: 15053478
Clin J Gastroenterol. 2012 Dec;5(6):373-6
pubmed: 26181316
Am Soc Clin Oncol Educ Book. 2013;:182-8
pubmed: 23714495
Int J Surg. 2016 Oct;34:180-186
pubmed: 27613565
Surg Oncol Clin N Am. 2012 Oct;21(4):635-43
pubmed: 23021721
Cancer Causes Control. 2009 Aug;20(6):935-44
pubmed: 19294523
Int J Colorectal Dis. 2015 Jan;30(1):1-10
pubmed: 25331029